Related Experiment Video
Updated: Jan 28, 2026

Multiplex PCR Assay for Typing of Staphylococcal Cassette Chromosome Mec Types I to V in Methicillin-resistant Staphylococcus aureus
Published on: September 5, 2013
Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
Matthildi Valianou1,2, Natalia Filippidou1,2, Daniel L Johnson3
1Division of Pediatric Nephrology, Department of Pediatrics, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA.
Abstract:
Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) are caused by inactivating mutations in TSC1 or TSC2, leading to mTORC1 hyperactivation. The mTORC1 inhibitors rapamycin and analogs (rapalogs) are approved for treating of TSC and LAM. Due to their cytostatic and not cytocidal action, discontinuation of treatment leads to tumor regrowth and decline in pulmonary function. Therefore, life-long rapalog treatment is proposed for the control of TSC and LAM lesions, which increases the chances for the development of acquired drug resistance. Understanding the signaling perturbations leading to rapalog resistance is critical for the development of better therapeutic strategies. We developed the first Tsc2-null rapamycin-resistant cell line, ELT3-245, which is highly tumorigenic in mice, and refractory to rapamycin treatment. In vitro ELT3-245 cells exhibit enhanced anchorage-independent cell survival, resistance to anoikis, and loss of epithelial markers. A key alteration in ELT3-245 is increased β-catenin signaling. We propose that a subset of cells in TSC and LAM lesions have additional signaling aberrations, thus possess the potential to become resistant to rapalogs. Alternatively, when challenged with rapalogs TSC-null cells are reprogrammed to express mesenchymal-like markers. These signaling changes could be further exploited to induce clinically-relevant long-term remissions.
Insights
Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) treatments face resistance due to cell reprogramming. Understanding these changes is key to developing therapies for long-term remission in TSC and LAM patients.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) stem from TSC1/TSC2 mutations, causing mTORC1 overactivation.
- Rapalogs, mTORC1 inhibitors, treat TSC and LAM but are cytostatic, necessitating lifelong use and risking drug resistance.
- Acquired resistance to rapalogs is a significant clinical challenge, driving the need to understand resistance mechanisms.
Purpose of the Study:
- To investigate the signaling pathways and cellular changes that lead to acquired resistance to rapalogs in TSC and LAM.
- To develop a cellular model for studying rapalog resistance in Tuberous Sclerosis Complex.
Main Methods:
- Development of the first Tsc2-null rapamycin-resistant cell line (ELT3-245) from a Tuberous Sclerosis Complex model.
- In vitro characterization of ELT3-245 cells for anchorage-independent survival, anoikis resistance, and epithelial marker expression.
- Analysis of key signaling alterations, including β-catenin pathway activation, in resistant cells.
Main Results:
- The ELT3-245 cell line demonstrated high tumorigenicity in mice and resistance to rapamycin.
- ELT3-245 cells exhibited increased survival independent of anchorage and resistance to programmed cell death (anoikis).
- A significant increase in β-catenin signaling was observed in the resistant cell line, alongside a loss of epithelial markers.
Conclusions:
- Rapamycin-resistant cells may arise from pre-existing signaling aberrations or reprogramming of Tsc2-null cells towards a mesenchymal-like phenotype.
- Increased β-catenin signaling and mesenchymal transition are potential mechanisms underlying rapalog resistance in TSC and LAM.
- Targeting these acquired signaling changes could lead to improved therapeutic strategies for achieving long-term remissions in TSC and LAM.
More Related Videos
Related Concept Videos
Mesenchymal Stem Cells
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Resistivity
Resistance
Types of Genetic Transfer Between Organisms
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...

